Clinical relevance of uPA, uPAR, PAI 1, PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F11%3A%230000183" target="_blank" >RIV/00209805:_____/11:#0000183 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=22234062&dopt=abstractplus" target="_blank" >http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=22234062&dopt=abstractplus</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5754/hge10232" target="_blank" >10.5754/hge10232</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical relevance of uPA, uPAR, PAI 1, PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients

Popis výsledku v původním jazyce

Background/Aims: Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PM 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. Methodology: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. Results: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0,010) and uPAR (p=0.019)

Název v anglickém jazyce

Clinical relevance of uPA, uPAR, PAI 1, PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients

Popis výsledku anglicky

Background/Aims: Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PM 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. Methodology: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. Results: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0,010) and uPAR (p=0.019)

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hepato-gastroenterology

ISSN

0172-6390

e-ISSN

—

Svazek periodika

58

Číslo periodika v rámci svazku

112

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

8

Strana od-do

1918-1925

Kód UT WoS článku

000300532700015

EID výsledku v databázi Scopus

—